Action SNOA SONOMA PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Sonoma Pharmaceuticals, Inc.

Actions

SNOA

US83558L2043

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
0,2122 USD +1,05 % Graphique intraday de Sonoma Pharmaceuticals, Inc. +5,21 % +17,63 %
17/06 Sonoma Pharmaceuticals, Inc. annonce ses résultats pour l'exercice clos le 31 mars 2024 CI
09/05 Sonoma Pharmaceuticals annonce que MicrocynAH pour la santé animale est désormais disponible dans les magasins de bricolage Menards CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results
AQ
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
AQ
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
AQ
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
AQ
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
AQ
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union through Sonoma's Extensive Distributor Network
AQ
Sonoma Pharmaceuticals : Material Agreement - Form 8-K
PU
Sonoma Pharmaceuticals : Investor Presentation October 2023 - Form 8-K
PU
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
AQ
Sonoma Pharmaceuticals : Regulation FD Presentation - Form 8-K
PU
SONOMA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SONOMA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
AQ
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
AQ
Sonoma Pharmaceuticals : Material Agreement - Form 8-K
PU
SONOMA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results
AQ
SONOMA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SONOMA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
SONOMA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SNOA
  4. Actualités Sonoma Pharmaceuticals, Inc.
  5. Communiqués